Cartilage-derived morphogenetic protein-1 and -2 are endogenously expressed in healthy and osteoarthritic human articular chondrocytes and stimulate matrix synthesis  by Bobacz, K. et al.
Osteoarthritis and Cartilage (2002) 10, 394–401
© 2002 OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All rights reserved. 1063–4584/02/$35.00/0
doi:10.1053/joca.2002.0522, available online at http://www.idealibrary.com onCartilage-derived morphogenetic protein-1 and -2 are endogenously
expressed in healthy and osteoarthritic human articular chondrocytes
and stimulate matrix synthesis
K. Bobacz*, R. Gruber†, A. Soleiman‡, W. B. Graninger*, F. P. Luyten§ and L. Erlacher*
*Department of Rheumatology, Internal Medicine III, University of Vienna, Austria
†School of Dentistry, Department of Oral Surgery, University of Vienna, Austria
‡Department of Pathology, University of Vienna, Austria
§Division of Rheumatology, University Hospitals, KULeuven, Belgium
Summary
Objective: We investigated whether chondrocytes derived from osteoarthritic cartilage may lose their responsiveness to cartilage-derived
morphogenetic protein-1, -2 (CDMP-1, -2) and osteogenic protein-1 (OP-1) compared with healthy cells, thus leading to an impaired
maintenance of matrix integrity.
Design: Chondrocytes were isolated from articular cartilage from patients with and without osteoarthritic lesions. Cells were grown as
monolayer cultures for 7 days in a chemically defined serum-free basal medium (BM) in the presence of recombinant CDMP-1, -2, and OP-1.
Glycosaminoglycan synthesis was measured by [35S]Sulfate incorporation into newly synthesized macromolecules. Cell proliferation was
investigated by [3H]Thymidine incorporation. The endogenous gene expression of CDMPs/OP-1 and their respective type I and type II
receptors was examined using RT-PCR. The presence of CDMP proteins in tissue and cultured cells was detected by Western immunoblots.
Results: mRNAs coding for CDMPs and their respective receptors are endogenously expressed not only in healthy, but also in osteoarthritic
cartilage. CDMP proteins are present in both normal and osteoarthritic articular cartilage and cultured chondrocytes. CDMP-1, CDMP-2 and
OP-1 markedly increased glycosaminoglycan synthesis in both healthy (P<0.01) and osteoarthritic (P<0.05) human articular chondrocytes.
A comparison of the glycosaminoglycan biosynthetic activity between healthy and osteoarthritic samples revealed no detectable difference,
neither in stimulated nor in unstimulated cultures. [3H]Thymidine incorporation showed that CDMPs/OP-1 did not affect cell proliferation
in vitro.
Conclusion: CDMPs and OP-1 exert their anabolic effects on both healthy and osteoarthritic chondrocytes indicating no loss in
responsiveness to these growth factors in OA. The endogenous expression of CDMPs/OP-1 and their receptors suggest an important role
in cartilage homeostasis. © 2002 OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All rights reserved.
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Articular cartilage is a unique connective tissue that pro-
vides mechanical resistance to compression and shear
forces as well as smooth and frictionless joint movement.
These functions are essentially dependent on a precisely
balanced physiological steady state between matrix degra-
dation and replenishment. In osteoarthritis (OA), the most
common rheumatic disease1, this metabolic equilibrium is
compromised, thus causing a progressive loss of extracel-
lular cartilaginous matrix that leads to a disruption of the
cartilage integrity, and subsequently to a destruction of the
joint surface2. Although the understanding of the pathogen-
esis of OA has evolved considerably over the past years,
the molecular mechanisms are still not clear. In theory,
a failure of cartilage homeostasis, such that anabolic394processes become relatively deficient in comparison with
catabolic ones may be viewed as the final pathway
common to different causes3.
Polypeptide growth factors are actively involved in regu-
lating matrix production and repair4,5. Since they can also
inhibit catabolic processes, a loss in chondrocytes’ respon-
siveness to growth factor stimulation may be an important
factor in the development of OA. Among the growth factors
involved in cartilage metabolism, cartilage-derived morpho-
genetic proteins-1 and -2 (CDMP-1 and CDMP-2), the
respective human homologs of mouse growth/
differentiation factors-5 and -6, may be of importance for
cartilage maintenance and repair. These morphogens are
members of the large transforming growth factor- (TGF-)
superfamily and they are closely related to the bone mor-
phogenetic protein (BMP) subgroups BMP-5/BMP-6/
osteogenic protein-1 (OP-1) and BMP-2/BMP-4. Both
growth factors, first simultaneously and independently
described by Chang et al. and Storm et al., are essential for
the formation of cartilaginous tissue during embryonic limb
development6–8. CDMP-1 and CDMP-2 exert their biologi-
cal effects through binding to a heteromeric receptor com-
plex of type I (preferentially BMP-receptor Ib or ALK-6) andReceived 11 May 2001; accepted 5 December 2001.
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predominantly expressed at the stage of pre-cartilaginous
mesenchymal condensations, subsequently around the
cartilaginous cores of developing long bones, but most
strikingly it is an excellent marker for the joint interzone11.
CDMP-2 was found in different locations but mostly
restricted to hypertrophic chondrocytes of ossifying long
bone centers6. The physiological role of CDMP-1 has been
established by its linkage to skeletal disorders, Hunter-
Thompson chondrodysplasia, Grebe chondrodysplasia and
brachydactyly12–14 and thus provide evidence for the cru-
cial involvement of CDMP-1 in human embryonic limb
patterning and development. However, the role of CDMP-1
and CDMP-2 in post-natal cartilage is largely unknown.
In the present study we investigated the stimulatory
effects of CDMP-1, CDMP-2 as well as OP-1 on matrix
macromolecule synthesis, glycosaminoglycan (GAG) syn-
thesis respectively, in post-natal human articular chondro-
cytes derived from healthy and osteoarthritic joints. We
hypothesized that a loss of responsiveness to the indicated
growth factors may be associated with an impaired matrix
maintenance in osteoarthritic cartilage compared to healthy
cells. Our findings demonstrate that CDMP-1, CDMP-2 and
OP-1 increase the GAG biosynthetic activity of postnatal
human articular chondrocytes independent of underlying
OA disease. Furthermore the endogenous expression of
CDMPs/OP-1 as well as their respective receptors was
shown in both, healthy and osteoarthritic tissue.RNA ISOLATION AND NORTHERN BLOT ANALYSIS
Total RNA was extracted using the modified acid
guanidine-phenol-chloroform method established by
Chomczynski and Sacchi16. For Northern blot analysis
equal amounts (5 g) of total RNA, determined by A260,
were electrophoresed on 1.2% agarose-formaldehyde gels
and transferred onto Nytran membranes (Schleicher andMaterials and Methods
GROWTH FACTORS
CDMP-1, CDMP-2 and OP-1 were kindly provided by
Stryker Biotech (Hopkinton, MA, USA). Aliquots were
stored at −80°C.CELL CULTURE
Human articular cartilage from 17 patients (aged 37 to 80
years; mean age: 58.6 years) without macroscopic osteoar-
thritic lesions were obtained from surgical specimens at the
time of endoprosthetic replacement for acute transcervical
fractures and from organ donors. The removal of cartilage
from organ donors was approved by the ethics committee
of the University of Vienna. Osteoarthritic cartilage samples
were obtained from 13 individuals, who underwent surgery
for total hip endoprosthesis. The age of the patients ranged
from 35 to 84 years with a mean age of 58.8 years.
Cartilage slices were aseptically dissected from the
load-bearing joint surfaces, avoiding neocartilage at the
margins of OA specimens, and finely minced. Chondro-
cytes were released by overnight digestion in 0.2% colla-
genase B (Boehringer Mannheim, Mannheim, Germany) at
37°C in a shaking waterbath. An aliquot of 50 l of the
isolated cells was stained with 50 l Trypanblue for viability
assessments.
Isolated cells were grown as monolayer cultures in a 1:1
mixture of Dulbecco’s Modified Eagle’s Medium (DMEM
25 mM Hepes+4500 mg/l glucose+pyridoxine, without
sodium pyruvate; Life Technologies, Gaithersburg, MD,
U.S.A.) and Ham’s F12 (Ham’s F-12+L-glutamine; Life
Technologies) containing 10% (v/v) FBS (PAA Laborato-
ries, Linz, Austria) and antibiotics/antimycotics (100 U/ml
penicillin G, 100 mg/ml streptomycin, and 0.25 g/ml
amphotericin B; Life Technologies). For GAG synthesis andcell proliferation assays, primary chondrocytes were plated
in 24 multiwell-plates (Costar, Cambridge, MA, U.S.A.) in
quadruplicates at a density of 2×105 cells/well. At 90%
confluence chondrocyte cultures were switched to a
recently described chemically defined serum free basal
medium (BM)9. Over a period of 7 days growth factors and
BM were added as needed and culture medium was
replaced every second day. Cultures were maintained at
37°C in humidified air and 5% CO2.
For total RNA preparation, 2×106 primary cells were
seeded in 100 mm tissue-culture dishes (Costar) and
cultured as described above.PROTEIN CONTENT
At the end of the 7-day stimulation period chondrocytes
were suspended in 0.5 ml/well PBS (phosphate-buffered
saline; GibcoBRL, Life Technologies, Paisley, Scotland)
containing 0.05% (v/v) Triton X-100. Cells were disrupted
by ultrasound (Vibra Cell; Sonics & Materials Inc.;
Danbury, CT, U.S.A.) and aliquots were transferred to
96-well plates (Costar). Two hundred l chromogenous
solution (Bio-Rad Protein Assay; Bio Rad Laboratories
GmbH, Munich, Germany) were added and samples were
measured using an ELISA-Reader (Dynatch MR 7000;
Guernsey, Channel Islands, U.K.).BIOSYNTHESIS OF MACROMOLECULES
GAG synthesis rate, as determined by [35S]sulfate incor-
poration into sulfated macromolecules, was evaluated as
previously described15. Briefly, cells were labeled with
20 Ci/ml of [35S]sulfate (carrier-free, Amersham Pharma-
cia Biotech, Uppsala, Sweden) for 6 hours at 37°C in
serum-free BM. Cultures were extracted in guanidine-HCl
buffer (4 M guanidine-HCl, 50 mM sodium acetate buffered
at pH 7.2, in the presence of protease inhibitors). Unincor-
porated isotope was removed using Sephadex G-25
(PD-10 columns; Amersham Pharmacia Biotech) gel filtra-
tion chromatography in the guanidine-HCl buffer. Aliquots
from void volume fractions were measured by liquid
scintillation counting (1410 liquid scintillation counter;
Wallac Oy, Turku, Finland) and normalized for cellular
protein content.CELL PROLIFERATION
Cell proliferation was determined after a 7-day stimula-
tion period by adding 1 Ci/ml of methyl-[3H]Thymidine
(Amersham Pharmacia Biotech) to the cultures for the last
24 h of the culture period. Cells were then washed twice
with PBS, suspended in 0.05% Triton X-100 solution and
transfered to a filter matrix. Radioactivity uptake was ana-
lysed in a scintillation counter (1205 Betaplate: Wallac
Oy, Turku, Finland). Positive controls (BM containing 10%
FBS) were run in parallel.
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blots were pre-hybridized at 68°C for 30 min in hybridiza-
tion buffer (Express Hyb, Clontech, Palo Alto, CA, U.S.A.),
and hybridisation was performed with [-32P]deoxycytidine
triphosphate-labeled (Amersham Pharmacia Biotech)
cDNA fragments for 1 h at 68°C. cDNA fragments of
aggrecan, type II collagen, and -actin (Table I) were
amplified by RT-PCR, purified, and labeled using a random
hexanucleotide-primed second-strand synthesis method.
Membranes were subsequently washed three times in
2×saline-sodium citrate (SSC), 0.05% sodium dodecyl
sulfate (SDS), twice in 0.2×SSC, 0.1% SDS at room
temperature for 10 min and then exposed to Kodak XAR-5
film at −70°C for up to 24 h. Densitometry analysis was
performed using ‘Quantity One’ software (Bio-Rad Labora-
tories, Hercules, CA, U.S.A.) and values were normalized
for -actin content.WESTERN BLOT ANALYSIS
For Western blot analysis, chondrocytes from healthy
and osteoarthritic joints were isolated and cultured in 24
multiwell plates (Costar) at a density of 2×105 cells/well, as
described above until confluence. After washing the wells
with PBS (GibcoBRL) three times, 50 l of sample buffer
(NuPAGE LDS sample buffer (4×); Invitrogen Corporation;
Carlsbad, CA, U.S.A.) per well were added. Cells were
disrupted by ultrasound and samples were stored at
−80°C.
For cartilage extraction, slices of freshly isolated articular
cartilage (0.5 to 1 g wet weight) were washed with PBS,
finely minced and extracted in guanidine-HCl buffer (1 M
guanidine-HCl, 50 mM sodium acetate buffered at pH 7.2)
in the presence of protease inhibitors for 3 h at 4°C and
subsequently dialysed (Slide-A-Lyzer® Dialysis Cassette;
Pierce; Rockford, IL, U.S.A.) against water for 48 h at 4°C.
Extracts were then lyophilized and resuspended in sample
buffer (NuPAGE LDS sample buffer) to which 8 M urea was
added and stored at −80°C.
Aliqots of samples (optimal volume of 1 l per lane was
determined by sample dilution) were analysed under
reduced conditions (10% dithioerythritol). Samples were
boiled for 5 min in a water bath at 95°C and loaded onto a
10% Bis-Tris gel (NuPAGE 10% Bis-Tris Gel; Invitrogen
Corporation). Electrophoresis was carried out in a commer-
cially available running buffer (NuPAGE MOPS SDS run-
ning buffer (20×); Invitrogen Corporation) at 200 V for
50 min. Proteins were transferred from the gel onto a
nitrocellulose membrane for 90 min at 30 V in a buffer
containing 0.4 M Glycine, 0.5 M Tris base and 0.01 M SDS.
Non-specific binding sites were blocked with 4% bovine
serum albumin for 30 min. Blots were then probed with
polyclonal antibodies against CDMP-1 and -220 and
thereafter incubated with an appropriate horseradish
peroxidase-conjugated secondary antibody (Jackson
ImmunoResearch Laboratories Inc.; West Grove, PA,
U.S.A.) at a dilution of 1:50,000. For detection enhance-
ment 1 ml of a chemiluminescent substrate (SuperSignal®
West Pico Chemiluminescent Substrate; Pierce) was
applied to the membrane. Recombinant CDMP-1 and -2
were used as positive controls, sample buffer served as
negative control. Blots were visualized on Kodak X-OmatTable I
Primer sequences of oligonucleotides
mRNA template Primer sequence
(forward)
Primer sequence
(reverse)
Aggrecan17 5′-cgc tac gac gcc atc tgc tac-3′ 5′-gcc tgc tgt gcc tcc tca aa-3′
Type II collagen17 5′-atg aca atc tgg ctc cca ac-3′ 5′-gcc cta tgt cca cac cga att-3′
-Actin 5′-tgt gat ggt ggg aat ggg tca g-3′ 5′-ttt gat gtc acg cac gat ttc c-3′
TGF- superfamily receptor type I (AKL-1)18 5′-cga cgg agg cag gag aag cag-3′ 5′-tga agt cgc ggt ggg caa tgg-3′
Activin A receptor, type I (ALK-2)18 5′-gag tga tga ttc ttc ctg tgc-3′ 5′-ttg gtg gtg atg agc cct tcg-3′
Bone morphogenetic protein receptor, type IA (ALK-3)18 5′-aaa agt ggc ggt gaa agt att-3′ 5′-agt ctg gag gct gga ttg tgg-3′
Activin A receptor, type IB (ALK-4)18 5′-gag atc gtg ggc acc caa ggg-3′ 5′-agc tgg gag agg gtc ttc ttg-3′
Transforming growth factor, beta receptor I (ALK-5)18 5′-gat ggg ctc tgc ttt gtc tct-3′ 5′-tgt ctt tat tgt ctg ctg cta-3′
Bone morphogenetic protein receptor, type IB (ALK-6)19 5′-tac aag cct gcc ata agt gag aag c-3′ 5′-atc atc gtg aaa caa tat ccg tct g-3′
BMPR-II (BMPR-II)19 5′-tcc tct cat cag cca ttt gtc ctt tc-3′ 5′-agt tac tac aca ttc ttc ata g-3′
Activin type II receptor (ActR-II)18 5′-gca aaa tga ata cga agt cta-3′ 5′-gca ccc tct aat acc tct gga-3′
Bone morphogenetic protein-7 (BMP-7/OP-1) 5′-atg gtg gct ttc ttc aag gc-3′ 5′-ttc agg atg acg ttg gag ct-3′
Cartilage-derived-morphogenetic Protein-1 (CDMP-1) 5′-acg gga cct gtt ctt taa tg-3′ 5′-ctt ata cac cac gtt gtt gg-3′
Cartilage-derived-morphogenetic Protein-2 (CDMP-2) 5′-gct ggg acg act gga tta tc-3′ 5′-tag acc aca tta ttg ccc gc-3′ANALYSIS OF CDMPS/BMP AND THEIR RESPECTIVE RECEPTORS
Total RNA of unstimulated chondrocyte cultures was
extracted as described for Northern analysis, and 1 g of
each sample was copied into cDNA in a 20 l reaction
using the First-Strand cDNA Synthesis Kit (Amersham
Pharmacia Biotech). One l aliquots were amplified in a
10 l reaction mixture that contained 50 mM Tris-HCl
(pH 8.3), 2 mM MgCl2, 0.25% bovine serum albumin, 2.5%
Ficoll 400, 5 mM tartrazine, 200 M of each dNTP, 1 M of
each primer, and 0.2 U Taq polymerase (Boehringer
Mannheim, Mannheim, Germany). The same reaction pro-
file was used for all primer sets: an initial denaturation at
94°C for 1 min, followed by 30 cycles of 94°C for 1 s;
52–64°C for 1 s; and 72°C for 40 s, and an additional 2 min
extension step at 72°C after the last cycle. Amplification
reactions were performed in an air thermal cycler (Idaho
Technology Inc., Idaho Falls, ID, U.S.A.). Primer
sequences used are listed in Table I. Reaction products
were analysed by electrophoresis in 1.5% agarose gels.
The amplified DNA fragments were stained with SYBR-
Green (Molecular Probes, Eugene, OR, U.S.A.) and visu-
alized with a Fluorimager (Molecular Dynamics, Sunnyvale,
CA, U.S.A.). Positive and negative controls were run in
parallel.
Osteoarthritis and Cartilage Vol. 10, No. 5 397Blue XB-1 imaging film. Densitometry was done using
‘Quantity One’ software (Bio-Rad) and values were
normalized to cartilage wet weight.was observed for both CDMP-1 (181±15%; P<0.001) and
CDMP-2 (150±13%; P<0.01). OP-1 was found to be two-
fold more stimulatory than CDMP-1 or CDMP-2 as deter-
mined by a 324±20% (P<0.001) increase in the
[35S]Sulfate incorporation rate [Fig. 3(a)].
The results obtained in osteoarthritic chondrocyte cul-
tures also showed a significant increase of [35S]Sulfate
incorporation into newly synthesized matrix macromol-
ecules in the presence of CDMP-1 (159±25%; P<0.05)
CDMP-2 (120±23%; P<0.05) and OP-1 (226±28%;
P<0.05) after 7 days in culture [Fig. 3(b)]. The comparisonFig. 1. Endogenous expression of CDMPs/OP-1 and their respec-
tive type I and type II receptors by human articular chondrocytes.
Total RNA was extracted from five randomly selected healthy
(healthy control=HC) and five osteoarthritic tissue specimens.
Subsequently RT-PCR was performed using 1 g of RNA from
each sample with primers for (a) CDMP-1, CDMP-2 and OP-1 and
(b) ALK-1 to ALK-6, ActRII and BMPRII and stained with SYBR-
Green. Equal loading of the samples was confirmed by -Actin
expression. Juvenile bovine articular chondrocytes served as
positive controls.STATISTICAL ANALYSIS
Data are expressed as mean and standard error of mean
(S.E.M.). Statistical analysis was performed using the
Student’s t-test to compare treated with untreated samples
and healthy with OA samples. Statistical significance was
defined as a P value <0.05. Software used: Microsoft®
Excel 7.0 and Graph Pad Prism® 3.00.Results
CDMPS/BMPS AND THEIR RESPECTIVE RECEPTORS ARE
ENDOGENOUSLY EXPRESSED BY HEALTHY AND OSTEOARTHRITIC
CHONDROCYTES
To investigate whether postnatal human articular
chondrocytes express CDMP-1, -2 and OP-1 as well as
their respective cell surface receptors, RT-PCR analysis of
total RNA obtained from cartilage of randomly selected
patients with and without underlying OA was performed.
When we examined the growth factor expression in these
specimens, mRNAs encoding for CDMP-1, CDMP-2 could
be detected [Fig. 1(a)]. RT-PCR of type I and type II
receptors for CDMPs/BMPs yielded fragments specific for
ALKs 1-6, ActR-II and BMPR-II in healthy as well as in
osteoarthritic tissue samples [Fig. 1(b)].
In addition, to determine the presence of CDMP-1 and -2
protein in postnatal human articular cartilage derived from
healthy and osteoarthritic joints by Western immunoblot-
ting, we analysed both, cell lysates (data not shown) and
cartilage extracts and demonstrated the presence of
CDMP-1 and -2 in healthy as well as osteoarthritic carti-
lage. Recombinant proteins served as positive controls
(Fig. 2). Higher concentrations of CDMP-2 positive controls
were used, since the recombinant protein is much less
detectable then the native protein due to discrete protein
sequence differences.
These data support a role of the indicated growth factors
as autocrine/paracrine mediator(s) in cartilage matrix
maintenance.CDMPS STIMULATE SYNTHESIS OF MATRIX MACROMOLECULES IN
CHONDROCYTES DERIVED FROM HEALTHY AND OSTEOARTHRITIC
CARTILAGE
A loss in the responsiveness of articular chondrocytes to
relevant growth factors may result in an impairment of
cartilage integrity. To obtain an insight into the pathogenic
mechanisms leading to the development or progression of
OA, we investigated whether chondrocytes derived from
osteoarthritic cartilage lose their responsiveness to the
cartilage-specific growth factors CDMP-1, CDMP-2, as well
as OP-1 compared to healthy controls.
Optimal concentrations of 100 ng/ml for CDMP-1, -2 as
well as OP-1, as previously shown by Erlacher et al.20 and
reconfirmed by dose/response analysis (data not shown),
were used in all experiments. In healthy chondrocyte cul-
tures, growth factor treatment resulted in an increase of
[35S]Sulfate incorporation into newly synthesized GAGs
compared to cultures maintained in BM alone. This effect
398 K. Bobacz et al.: CDMPs in human articular chondrocytesbetween healthy and osteoarthritic chondrocytes showed
no significant difference between healthy and osteoarthritic
tissue samples, neither for unstimulated nor stimulated
cultures, suggesting no change in growth factor
responsiveness in osteoarthritic cartilage.Fig. 2. Detection of CDMP-1 and -2 in extracts from healthy (N=2) and OA (N=3) human articular cartilage. Polyclonal antibodies against
the N-terminal domain of the mature region of CDMP-1 and CDMP-2 detected the indicated growth factors in 1 M guanidine-HCl extracts of
post-natal human articular cartilage under reduced conditions. Recombinant CDMP-1 and CDMP-2 were run in parallel at different
concentrations as positive controls. Sample buffer served as negative control. Molecular weight markers are shown at the right.0
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Fig. 3. Effects of CDMP-1, CDMP-2 and OP-1 on glycosaminogly-
can synthesis of postnatal human articular chondrocytes.
Chondrocytes derived from (a) healthy (N=17) and (b) osteoar-
thritic (N=13) cartilage were incubated in serum-free basal
medium (BM) with or without the addition of CDMP-1 (100 ng/ml),
CDMP-2 (100 ng/ml) and OP-1 (100 ng/ml). On day 7 of the
stimulation period cell cultures were labeled with [35S]Sulfate for
6 h. The incorporated radiolabel into newly synthesized matrix
macromolecules present in the cell layer was then measured,
normalized to protein content and given as counts per min/mg
protein (cpm/mg protein). Values are the mean and S.E.M. *P<0.05
vs BM, **P<0.01 vs BM, ***P<0.001 vs BM.NORTHERN BLOT ANALYSIS OF MRNA EXPRESSION OF AGGRECAN
AND COLLAGEN TYPE II
Further analysis of chondrocyte biosynthesis was per-
formed using Northern blot analysis of the cartilage
markers aggrecan and type II collagen. In both, healthy and
osteoarthritic chondrocytes, cultured in the presence of the
indicated growth factors, CDMP-1, CDMP-2 and OP-1
highly increased aggrecan mRNA levels, when densities of
aggrecan mRNA bands were normalized to densities of
-Actin bands (Fig. 4). The expression of type II collagen
mRNA was weak in both groups and not appreciably
enhanced by either CDMP-1, CDMP-2 or OP-1 (data not
shown).
To determine a possible stimulatory effect of CDMP-1
and CDMP-2 as well as OP-1 on cell proliferation, the rate
of [3H]Thymidine incorporation was assessed in healthy
and osteoarthritic chondrocytes. Our data revealed that
chondrocyte proliferation was not affected by growth factor
treatment, either in healthy or in osteoarthritic cartilage
(data not shown).Discussion
This study compared the stimulatory effects of CDMP-1
and CDMP-2 on matrix macromolcule synthesis in healthy
and osteoarthritic post-natal human articular chondrocytes.
Furthermore, the endogenous expression profile of
CDMPs/OP-1 and their respective receptors was investi-
gated. We found no difference in GAG biosynthesis
between healthy and osteoarthritic samples treated with
CDMP-1 and CDMP-2 or OP-1. Moreover growth factors
and their specific type-I and type-II receptors were
Osteoarthritis and Cartilage Vol. 10, No. 5 399endogenously expressed in cartilage with and without
underlying OA disease. These findings suggest a potential
role for the investigated growth factors, as anabolic media-
tors in the maintenance and repair of articular cartilage,
both in postnatal healthy as well as osteoarthritic human
cartilaginous tissue.
It has been well established that members of the BMP
family have the ability to increase cartilage matrix syn-
thesis, as shown in chondrocyte cultures derived from
animal and human articular cartilage15,22–25. However,
studies on the stimulatory effects of CDMP-1 and CDMP-2
on cartilage metabolism are few. Erlacher and co-workers
previously reported that these cartilage specific growth
factors enhance GAG synthesis in fetal human and post-
natal bovine articular chondrocytes20. However, the impor-
tance of CDMPs in mediating an up-regulation of matrix
biosynthetic activity in adult human cartilage remains
unclear. Our recent in vitro study showed the potential of
CDMP-1 and CDMP-2 to increase the de novo GAG
biosynthesis of postnatal human articular chondrocytes, as
determined by [35S]Sulfate incorporation into newly synthe-
sized matrix macromolecules, supporting a role of CDMP-1
and CDMP-2 in the maintenance of cartilage homeostasis.
Moreover, CDMP-1 and CDMP-2 have been shown to
increase matrix macromolecule synthesis by articular
chondrocytes in an enzymatically depleted cartilage
explant model20. In this regard we extended our observa-
tions by investigating the stimulatory effects of CDMP-1
and CDMP-2 on human articular chondrocytes derived
from osteoarthritic joints, hypothesizing that a loss of
responsiveness of osteoarthritic chondrocytes, compared
to healthy cells, may disturb the equilibrium between ana-
bolic and catabolic mediators and subsequently lead to
metabolic deterioration of the cartilage matrix. This hypoth-
esis was based on the findings of Dore´ and Tardif, who
reported that osteoarthritic chondrocytes show a decrease
in the responsiveness to insulin-like growth factor-I26,27. In
our culture settings we did not find any statistical difference
in the rate of GAG synthesis between healthy and
osteoarthritic samples, thus demonstrating no loss of
responsiveness to CDMPs in osteoarthritic cartilage.
As shown by Brocklehurst and co-workers, who have
consistently found no differences in GAG biosynthetic ratebetween OA and normal age-matched cartilage samples
which were corrected for zonal and topographical cartilage
surface sampling sites28, we did not find a difference in
basal GAG synthesis between unstimulated healthy and
osteoarthritic cartilage cultures. Our data strongly suggest
that CDMP-1 and CDMP-2 contribute to the maintenance
and repair not only in healthy but also in osteoarthritic
post-natal human articular cartilage and further indicate
that OA pathogenesis is not associated with a lack of
response to CDMPs.
In recent years, an increasing number of autocrine or
paracrine growth regulators have been identified in articular
cartilage29–31. BMPs and their receptors were localized in
mouse and rat epiphysial growth plate32,33. Osteoarthritic
chondrocytes have also been shown to express various
growth factors including BMP-2 and TGF-34,35. CDMP-1
and CDMP-2 mRNA was found in healthy bovine cartilage
by Chang and co-workers using Northern blot analysis6.
Beyond that, immunohistochemical staining revealed the
presence of CDMP-1 and CDMP-2 in healthy as well as
osteoarthritic human cartilage at the protein level20. This
study extent these findings by Western immunoblotting
and, to the best of our knowledge, it is the first study to
examine the mRNA expression of CDMP-1 and CDMP-2 as
well as their respective receptors in postnatal healthy and
osteoarthritic human articular cartilage.
Our findings that healthy as well as osteoarthritic
chondrocytes endogenously express CDMPs support their
role in matrix maintenance. In addition, our study make
these findings more biologically/functionally meaningful by
demonstrating that independent of OA, post-natal human
articular chondrocytes express BMP specific type I/type II
serine/threonine kinase receptors. Surprisingly we found a
lack of OP-1 mRNA in osteoarthritic tissue samples. In
contrast to our data, Chubinskaya and co-workers, showed
the presence of pro- and mature OP-1 in extracts of normal
and osteoarthritic cartilages by Western blotting36. Our
inability to detect OP-1 mRNA may be due to an extremely
low level of the mRNA transcripts in osteoarthritic tissue
which is beyond the limit of detection. This is consistent
with the low levels of OP-1 mRNA detected in healthy
cartilage samples. Another explanation may be the
chondrocyte isolation and culture method that possiblyFig. 4. Northern blot analysis on the expression of the extracellular matrix molecule aggrecan in healthy and osteoarthric cartilage. The figure
shows a representative blot out of two experiments. Chondrocytes obtained from cartilage with and without osteoarthric lesions were cultured
in basal medium (BM) in the presence or absence of CDMP-1 (100 ng/ml), CDMP-2 (100 ng/ml) and OP-1 (100 ng/ml) for 7 days. Equal
amounts of total RNA from each culture (5 g) were separated on 1.2% agarose-formaldehyde gels, blotted and hybridized with
complementary DNA probes for aggrecan as described in materials and methods. Hybridization with the reference probe -Actin to verify
consistent loading of messenger RNA is shown at the bottom lane.
400 K. Bobacz et al.: CDMPs in human articular chondrocytesaffects OP-1 expression, thereby not reflecting the in vivo
situation. However, the mRNA expression of CDMPs/OP-1
and their respective receptors strongly suggest that these
growth factors are involved in maintaining a physiological
equilibrium of anabolic and catabolic mediators possibly
in an autocrine/paracrine manner in post-natal human
articular chondrocytes.
In conclusion, our findings demonstrate that CDMP-1
and CDMP-2 increase the GAG biosynthetic activity of
post-natal human articular chondrocytes of healthy as well
as osteoarthritic chondrocytes. Our conclusions are based
on the measurement of matrix macromolecule synthesis,
thus we cannot rule out other, differentially regulated effects
of CDMP/OP-1 in osteoarthritic cartilage, such as collagen
synthesis or matrix-metalloproteinase expression. How-
ever, as OA is not associated with a lack of growth factor
expression/responsiveness in the resident cells, CDMPs/
OP-1 may not be critically involved in the progression
of OA disease, but rather in the maintenance of tissue
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